The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study
Information on depressive symptoms among patients with atopic dermatitis (AD) undergoing systemic treatment in a real-world setting is scarce. This prospective real-world clinical cohort study analysed data from SwedAD, a Swedish national register comprising patients with AD undergoing systemic trea...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2022-10-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actadv/article/view/803 |
| _version_ | 1798030734012710912 |
|---|---|
| author | Lina U. Ivert Axel Svedbom Maria Lundqvist Carl-Fredrik Wahlgren Maria Bradley Emma K. Johansson |
| author_facet | Lina U. Ivert Axel Svedbom Maria Lundqvist Carl-Fredrik Wahlgren Maria Bradley Emma K. Johansson |
| author_sort | Lina U. Ivert |
| collection | DOAJ |
| description | Information on depressive symptoms among patients with atopic dermatitis (AD) undergoing systemic treatment in a real-world setting is scarce. This prospective real-world clinical cohort study analysed data from SwedAD, a Swedish national register comprising patients with AD undergoing systemic treatment. Data were collected at baseline (n = 120) and at follow-up at 6 months (range 3–9 months, n = 59), and 12 months (10 months or later, n = 36). Depression was assessed with the Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S) and AD with the Eczema Area Severity Index, the Patient-Oriented Eczema Measure, the Dermatology Life Quality Index and evaluation of pruritus. More than half of patients with moderate-to-severe AD had depressive symptoms at baseline, 24% presented with moderate-to-severe depression and 3% had pronounced suicidal ideation. Systemic treatment of AD significantly reduced both depression and AD symptoms at 6 months, and this positive effect remained at 12 months. In conclusion, depressive symptoms are common among adults with moderate-to-severe AD. Systemic treatment of AD significantly reduced depressive symptoms in parallel with AD symptoms.
|
| first_indexed | 2024-04-11T19:44:59Z |
| format | Article |
| id | doaj.art-7eac4db9870c4855ab86d638d1d5f997 |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-04-11T19:44:59Z |
| publishDate | 2022-10-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-7eac4db9870c4855ab86d638d1d5f9972022-12-22T04:06:30ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572022-10-0110210.2340/actadv.v102.803The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort StudyLina U. Ivert0Axel Svedbom1Maria Lundqvist2Carl-Fredrik Wahlgren3Maria Bradley4Emma K. JohanssonDermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, SE-171 76 Stockholm, Sweden1Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska InstitutetDepartment of Dermatology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska InstitutetDermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet. Department of Dermatology, Karolinska University HospitalInformation on depressive symptoms among patients with atopic dermatitis (AD) undergoing systemic treatment in a real-world setting is scarce. This prospective real-world clinical cohort study analysed data from SwedAD, a Swedish national register comprising patients with AD undergoing systemic treatment. Data were collected at baseline (n = 120) and at follow-up at 6 months (range 3–9 months, n = 59), and 12 months (10 months or later, n = 36). Depression was assessed with the Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S) and AD with the Eczema Area Severity Index, the Patient-Oriented Eczema Measure, the Dermatology Life Quality Index and evaluation of pruritus. More than half of patients with moderate-to-severe AD had depressive symptoms at baseline, 24% presented with moderate-to-severe depression and 3% had pronounced suicidal ideation. Systemic treatment of AD significantly reduced both depression and AD symptoms at 6 months, and this positive effect remained at 12 months. In conclusion, depressive symptoms are common among adults with moderate-to-severe AD. Systemic treatment of AD significantly reduced depressive symptoms in parallel with AD symptoms. https://medicaljournalssweden.se/actadv/article/view/803Atopic dermatitisatopic eczemadepressionsuicidal ideationdrug therapyepidemiology |
| spellingShingle | Lina U. Ivert Axel Svedbom Maria Lundqvist Carl-Fredrik Wahlgren Maria Bradley Emma K. Johansson The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study Acta Dermato-Venereologica Atopic dermatitis atopic eczema depression suicidal ideation drug therapy epidemiology |
| title | The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study |
| title_full | The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study |
| title_fullStr | The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study |
| title_full_unstemmed | The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study |
| title_short | The Impact of Systemic Treatment of Atopic Dermatitis on Depressive Symptoms: A Prospective Clinical Cohort Study |
| title_sort | impact of systemic treatment of atopic dermatitis on depressive symptoms a prospective clinical cohort study |
| topic | Atopic dermatitis atopic eczema depression suicidal ideation drug therapy epidemiology |
| url | https://medicaljournalssweden.se/actadv/article/view/803 |
| work_keys_str_mv | AT linauivert theimpactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT axelsvedbom theimpactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT marialundqvist theimpactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT carlfredrikwahlgren theimpactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT mariabradley theimpactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT emmakjohansson theimpactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT linauivert impactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT axelsvedbom impactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT marialundqvist impactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT carlfredrikwahlgren impactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT mariabradley impactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy AT emmakjohansson impactofsystemictreatmentofatopicdermatitisondepressivesymptomsaprospectiveclinicalcohortstudy |